The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

Objective Treatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional imaging in response evaluation. However, real-life data on the benefit of TBP is scarce, especially from the limited resource settings and patients treate...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2023-07, Vol.149 (7), p.3599-3606
Main Authors: Guven, Deniz Can, Yekeduz, Emre, Erul, Enes, Yazgan, Sati Coskun, Sahin, Taha Koray, Karatas, Gokturk, Aksoy, Sercan, Erman, Mustafa, Yalcin, Suayib, Urun, Yuksel, Kilickap, Saadettin
Format: Article
Language:English
Subjects:
Cancer Research
Cohort analysis
Disease Progression
Hematology
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Internal Medicine
Lung Neoplasms - pathology
Medicine
Medicine & Public Health
Oncology
Retrospective Studies
Survival
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Treatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional imaging in response evaluation. However, real-life data on the benefit of TBP is scarce, especially from the limited resource settings and patients treated in the later lines. Therefore, we aimed to investigate the survival benefit of TBP with ICIs in patients with advanced tumors from a limited resource setting. Methods For this multi-center retrospective cohort study, we included 282 patients treated with ICIs and had radiological progression according to RECIST 1.1 criteria. We evaluated post-progression survival according to the use of TBP (TBP and non-TBP groups) with univariate and multivariate analyses. Results The cohort’s median age was 61, and 84.4% were treated in the second or later lines. 82 (29.1%) of 282 patients continued on ICIs following the initial progression. In multivariate analyses, patients in the TBP group had improved post-progression survival compared to non-TBP (13.18 vs. 4.63 months, HR: 0.500, 95% CI: 0.349–0.717, p  
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-022-04268-8